Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
25 avr. 2022 08h30 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome
15 mars 2022 08h41 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome
10 mars 2022 08h00 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
01 mars 2022 08h00 HE
|
Quoin Pharmaceuticals, Inc.
ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003 ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) --...
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome
17 févr. 2022 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Neopharm Gains Exclusive Rights to Commercialize QRX003 in IsraelSixth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE)...
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
10 févr. 2022 08h00 HE
|
Quoin Pharmaceuticals, Inc.
- ER-Kim Gains Exclusive Rights to Commercialize QRX003 Across Central & Eastern Europe - Fifth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb....
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome
26 janv. 2022 08h00 HE
|
Quoin Pharmaceuticals, Inc.
- OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America- Fourth Distribution Partnership Established Since Going Public in October 2021- Additional Territories in...
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome
15 déc. 2021 09h00 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin’s Lead Asset, QRX003
11 nov. 2021 08h30 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, and...
Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003
08 nov. 2021 08h00 HE
|
Quoin Pharmaceuticals, Inc.
AFT Gains Exclusive Rights to Commercialize QRX003 in Australia and New Zealand ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”),...